RAMM Pharma Corp. RAMM

Company Overview

RAMM Pharma Corp. is a Canadian life sciences and pharmaceutical company focused on cannabinoid-based pharmaceuticals, nutraceuticals, and cosmetic products. The company operates primarily in the regulated medical cannabis and cannabinoid therapeutics sector, with activities spanning pharmaceutical formulation, cultivation, extraction, clinical research, and international product commercialization. RAMM is publicly traded on the Canadian Securities Exchange under the ticker RAMM and has concentrated much of its operational activity in Latin America, particularly Uruguay and Brazil.

The company’s primary revenue drivers include the production and export of pharmaceutical-grade cannabinoid ingredients, medical cannabis products, and related wellness formulations. Through its subsidiaries, RAMM has developed vertically integrated capabilities that include cannabis cultivation, extraction, formulation development, and regulatory compliance for export markets. The company evolved from a broader cannabis-focused investment and operating model into a pharmaceutical-oriented cannabinoid business emphasizing international medical markets, especially jurisdictions with evolving cannabinoid regulatory frameworks and limited domestic production infrastructure.

Business Operations

RAMM Pharma conducts operations through several subsidiaries and operating units, including Medic Plast S.A., Yurelan S.A., and Canapar Corp. The company’s activities include the cultivation of cannabis in Uruguay, extraction and manufacturing of cannabinoid derivatives, pharmaceutical product development, and distribution into medical markets. Its operational structure is designed to support pharmaceutical-grade production standards and regulatory compliance for export-oriented cannabinoid products. Uruguay serves as a core production base due to the country’s federally regulated cannabis framework and export licensing system.

The company generates revenue through sales of cannabinoid formulations, bulk active pharmaceutical ingredients, and medical cannabis-related products, as well as through licensing and international commercial arrangements. RAMM has also pursued clinical and regulatory initiatives tied to cannabinoid therapeutics and veterinary applications. Its operations include intellectual property development around formulations and delivery systems, while strategic partnerships have supported access to international distribution channels, particularly in Latin American healthcare markets.

Strategic Position & Investments

RAMM Pharma’s strategic direction centers on expanding its pharmaceutical cannabinoid platform in regulated international markets with growing medical cannabis demand. The company has prioritized jurisdictions where medical cannabis regulations are advancing but local pharmaceutical supply remains constrained. Its strategy includes leveraging Uruguay’s federally legal cultivation and export environment to supply international markets with pharmaceutical-grade cannabinoid ingredients and finished products.

The company has invested in extraction infrastructure, cultivation capacity, and formulation development through subsidiaries such as Medic Plast S.A. and Yurelan S.A. RAMM has also pursued opportunities in veterinary cannabinoid products and wellness applications alongside human pharmaceutical development. Public disclosures and corporate filings indicate continued emphasis on regulatory approvals, export agreements, and commercial partnerships in Latin America and other international markets. While the company has referenced ongoing product development and market expansion initiatives, some future commercialization timelines and revenue expectations remain dependent on evolving regulatory approvals and market adoption.

Geographic Footprint

RAMM Pharma is headquartered in Toronto, Canada, while maintaining substantial operating activities in Uruguay, which functions as the company’s primary cultivation, extraction, and manufacturing jurisdiction. The company has focused much of its commercial strategy on Latin America, particularly Brazil and other emerging medical cannabis markets where pharmaceutical cannabinoid demand has increased alongside regulatory reform.

The company’s international footprint includes export-oriented operations and commercial relationships targeting markets in South America and potentially additional international jurisdictions where cannabinoid pharmaceuticals are permitted under medical frameworks. Uruguay remains strategically important due to its established federal cannabis regulations, export authorization systems, and comparatively mature cannabinoid production infrastructure relative to neighboring countries.

Leadership & Governance

RAMM Pharma operates under a leadership structure focused on pharmaceutical cannabinoid commercialization, international regulatory compliance, and vertically integrated production capabilities. Corporate governance is guided through public company reporting obligations and oversight associated with its Canadian public listing. The company’s strategic vision has emphasized disciplined expansion into regulated medical cannabis markets and pharmaceutical-grade manufacturing standards.

Key executives and leadership figures have included:

• Jack Burnett – Chief Executive Officer
• Peter Murray – Chief Financial Officer
• Marc Lustig – Director
• Barry Fishman – Director
• John Fowler – Director

Public company disclosures, including SEDAR filings, corporate presentations, and exchange filings, indicate that leadership has prioritized international medical market expansion, pharmaceutical compliance standards, and long-term cannabinoid product development. Certain executive and board compositions may change over time based on subsequent corporate filings and governance updates.